Ronquest NA, Paret K, Lucas A, Ciepielewska M, Hagan M. Quantifying the value of introducing an oral drug delivery option for edaravone: a review of analyses evaluating the economic impact of oral versus intravenous formulations. Clinicoecon Outcomes Res. 2022 Jul 27;14:499-511. doi: 10.2147/CEOR.S359025
Mahmoudi E, Lin P, Ratakonda S, Khan A, Kamdar N, Peterson MD. Preventative services use and risk reduction for potentially preventative hospitalizations among people with traumatic spinal cord injury. Arch Phys Med Rehabil. 2022 Jul;103(7):1255-62. doi: 10.1016/j.apmr.2021.12.004
Mareque M, Montesinos P, Font P, Guinea JM, de la Fuente A, Soto J, Oyaguez I, Brockbank J, Iglesias T, Llinares J, Sierra J. Cost-effectiveness analysis of gemtuzumab ozogamicin for first-line treatment of patients with Cd-33 positive acute myeloid leukaemia in Spain. Clinicoecon Outcomes Res. 2021 Apr 22;2021(13):263-77. doi: 10.2147/CEOR.S302097
Mladsi D, Barnett C, Aggarwal K, Vredenburg M, Dieterich D, Kim R. Cost-effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Clinicoecon Outcomes Res. 2020 Sep 14;2020(12):515-26. doi: 10.2147/CEOR.S262772
Bassali J, Gould IG, Kaye JA, Mladsi D, Mehta J. US budget impact model for selinexor in relapsed or refractory multiple myeloma. Clinicoecon Outcomes Res. 2020 Jun 19;12:317-25. doi: 10.2147/CEOR.S251070
Rajagopalan K, Candrilli SD, Ajmera M. Impact of antiepileptic drug-treatment burden on health-care-resource utilization and costs. Clinicoecon Outcomes Res. 2018 Oct 16;2018(10):619-27. doi: 10.2147/CEOR.S180913
Wilson MR, Azzabi Zouraq I, Chevrou-Severac H, Selby R, Kerrigan MC. Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK. Clinicoecon Outcomes Res. 2017 Oct 16;9:641-52. doi: 10.2147/CEOR.S135609
Porter W, Mahajan P, Danysh HE, Chelius DC. Socioeconomic determinants of pediatric papillary thyroid cancer: a SEER database review. Poster presented at the 87th Annual Meeting of the American Thyroid Association; October 21, 2017. Victoria, Canada. [abstract] Thyroid. 2017 Oct; 27(S1):A135-6.
Mahajan P, Danysh HE, Chelius DC, Venkatramani R. Characteristics and outcomes of children and adolescents with low-risk papillary thyroid carcinoma in the SEER database. Poster presented at the 87th Annual Meeting of the American Thyroid Association; October 20, 2017. Victoria, Canada. [abstract] Thyroid. 2017 Oct; 27(S1):A92.
Mahajan P, Danysh HE, Chelius DC, Venkatramani R. Characteristics and outcomes of children and adolescents with high-risk papillary thyroid carcinoma in the SEER database. Poster presented at the 87th Annual Meeting of the American Thyroid Association; October 20, 2017. Victoria, Canada. [abstract] Thyroid. 2017 Oct; 27(S1):A92-3.
Mao N, Lesher B, Liu Q, Qin L, Chen Y, Gao X, Earnshaw SR, McDade CL, Claudie C. Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infections in the People's Republic of China. Clinicoecon Outcomes Res. 2016 Jun;8:275-85.
Spinner DS, Birt J, Walter JW, Bowman L, Mauskopf J, Drummond MF, Copley-Merriman C. Do different clinical evidence bases lead to discordant health-technology assessment decisions? An in-depth case series across three jurisdictions. Clinicoecon Outcomes Res. 2013 Jan 1;5:69-85.
Boulanger L, Wu N, Chen SY, Nagar S, Fraser K, Bernauer MJ, Zhao Z, Zhao Y. Predictors of pain medication selection among patients diagnosed with fibromyalgia. Pain Pract. 2012 Apr;12(4):266-75.
Brodtkorb T, Henriksson M, Johannesen-Munk K, Thidell F. Cost-effectiveness of C-leg compared with non-microprocessor-controlled knees: a modeling approach. Arch Phys Med Rehabil. 2008;89(1):24-30.